Canakinumab for the Treatment of Postprandial Hypoglycemia

NCT05401578 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

56

Enrollment

OTHER

Sponsor class

Conditions

Postprandial Hypoglycemia

Interventions

DRUG: Canakinumab
DRUG: Placebo (0.9% NaCl)

Sponsor

University Hospital, Basel, Switzerland